Please wait while the formulary information is being retrieved.
ONCASPAR (PEGASPARGASE)
- Acute lymphoid leukemia
750 unit/mL injection solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Thrombotic disorder
Contraindicated
- Acute pancreatitis
- Hemorrhage
- Thromboembolic disorder
Severe
Moderate
- Hyperbilirubinemia
- Hyperglycemia
ONCASPAR (PEGASPARGASE)
- Acute lymphoid leukemia
- Acute pancreatitis
- Disease of liver
- Drug-induced hepatitis
- Hyperglycemia
- Fever
- Malaise
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Anorexia
- Arthralgias
- Hypoglycemic disorder
- Hypoproteinemia
- Hypotension
- Injection site sequelae
- Myalgias
- Tachycardia
- Tonic clonic seizure
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Bacterial sepsis
- Bone marrow depression
- Cerebral thrombosis
- Hemorrhage
- Hyperbilirubinemia
- Increased risk of bleeding due to coagulation disorder
- Leukopenia
- Necrotizing pancreatitis
- Thrombocytopenic disorder
- Thrombotic disorder
Less Severe
- Bronchospastic pulmonary disease
- Erythema
- Laryngeal edema
- Lip swelling
- Periorbital edema
- Skin rash
- Skin swelling
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pegaspargase
Safety and efficacy not established age <1 month.
- 1 Day – 29 Days
- Safety and efficacy not established age <1 month.
Pegaspargase
- Severity Level:
2
- Additional Notes:
Contraindicated
Pegaspargase
Not recommended. potential for serious adverse effects on infant
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Not recommended. potential for serious adverse effects on infant |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Acute lymphoid leukemia | |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
Formulary Reference Tool